NL9020094A - Behandeling van ziekte geassocieerd met hiv-infecties. - Google Patents
Behandeling van ziekte geassocieerd met hiv-infecties. Download PDFInfo
- Publication number
- NL9020094A NL9020094A NL9020094A NL9020094A NL9020094A NL 9020094 A NL9020094 A NL 9020094A NL 9020094 A NL9020094 A NL 9020094A NL 9020094 A NL9020094 A NL 9020094A NL 9020094 A NL9020094 A NL 9020094A
- Authority
- NL
- Netherlands
- Prior art keywords
- hiv
- cysteine
- acetyl
- hiv infection
- symptoms
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 35
- 208000031886 HIV Infections Diseases 0.000 title claims description 31
- 238000011282 treatment Methods 0.000 title description 13
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 38
- 229960004308 acetylcysteine Drugs 0.000 claims description 31
- 208000037357 HIV infectious disease Diseases 0.000 claims description 28
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 24
- 208000024891 symptom Diseases 0.000 claims description 23
- 208000030507 AIDS Diseases 0.000 claims description 19
- 235000018417 cysteine Nutrition 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 238000013518 transcription Methods 0.000 claims description 16
- 230000035897 transcription Effects 0.000 claims description 16
- 206010001513 AIDS related complex Diseases 0.000 claims description 14
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 13
- 229960002555 zidovudine Drugs 0.000 claims description 10
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 10
- 230000008506 pathogenesis Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 150000001944 cysteine derivatives Chemical class 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 17
- -1 NAC compounds Chemical class 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 9
- 239000002502 liposome Substances 0.000 description 7
- 108010024636 Glutathione Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920001744 Polyaldehyde Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000008747 mitogenic response Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30239689A | 1989-01-26 | 1989-01-26 | |
| US30239689 | 1989-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL9020094A true NL9020094A (nl) | 1991-10-01 |
Family
ID=23167578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL9020094A NL9020094A (nl) | 1989-01-26 | 1990-01-24 | Behandeling van ziekte geassocieerd met hiv-infecties. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5607974A (it) |
| JP (1) | JPH04504570A (it) |
| KR (1) | KR940002820B1 (it) |
| AU (1) | AU639686B2 (it) |
| BE (1) | BE1004168A3 (it) |
| CA (3) | CA1339256C (it) |
| CH (1) | CH683499A5 (it) |
| DE (1) | DE4090165T (it) |
| DK (1) | DK139191A (it) |
| FR (1) | FR2643557B1 (it) |
| GB (1) | GB2243296B (it) |
| GR (1) | GR900100048A (it) |
| IE (1) | IE62795B1 (it) |
| IL (1) | IL93162A (it) |
| IT (1) | IT1237999B (it) |
| LU (1) | LU87977A1 (it) |
| MA (1) | MA21739A1 (it) |
| MX (1) | MX173567B (it) |
| NL (1) | NL9020094A (it) |
| OA (1) | OA09503A (it) |
| PT (1) | PT92949B (it) |
| SE (1) | SE9101815D0 (it) |
| TN (1) | TNSN90009A1 (it) |
| WO (1) | WO1990008540A1 (it) |
| ZA (1) | ZA90245B (it) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5554655A (en) * | 1991-09-30 | 1996-09-10 | Jess G. Thoene | Method of treating HIV infection |
| MX9205549A (es) * | 1991-09-30 | 1993-05-01 | Jess G Thoene | Metodo para el tratamiento de vih. |
| EP0600462A1 (en) * | 1992-12-01 | 1994-06-08 | Nippon Flour Mills Co., Ltd. | Reverse transcriptase inhibitors and antiviral agents |
| AU6060694A (en) * | 1993-05-10 | 1994-11-17 | Transcend Therapeutics, Inc | Method for treating acquired immune deficiency syndrome |
| DE4325547C2 (de) * | 1993-07-29 | 1997-11-27 | Max Planck Gesellschaft | Verwendung von Thiolverbindungen zur Therapie von Hepatitis-_Viren-induzierten Erkrankungen |
| US5725870A (en) * | 1993-10-15 | 1998-03-10 | Thoene; Jess G. | Methods, composites and articles for contraception |
| CA2173964A1 (en) * | 1993-10-15 | 1995-04-20 | Jess G. Thoene | Prevention of hiv infection |
| US5786152A (en) * | 1996-04-26 | 1998-07-28 | Amgen Inc. | Methods of inhibiting syp binding to a CTLA-4 receptor |
| HUP9602024A3 (en) * | 1996-07-25 | 1999-05-28 | Toth Sandor | Pharmaceutical composition containing aminoacid for external use |
| TW517089B (en) | 1996-09-03 | 2003-01-11 | Res Dev Foundation | Assessment of intracellular cysteine and glutathione concentrations |
| ATE444760T1 (de) * | 1997-01-13 | 2009-10-15 | Univ Emory | Glutathion zur behandlung von influenzainfektionen |
| US6331610B1 (en) * | 1997-04-25 | 2001-12-18 | Metatron, Inc. | Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin |
| US6020205A (en) * | 1998-04-10 | 2000-02-01 | Immunosciences Lab, Inc. | Determination of intracellular antioxidant levels |
| US6251868B1 (en) * | 1998-04-30 | 2001-06-26 | Teijin Limited | Method for treating a human immunodeficiency virus infection |
| US6566401B2 (en) * | 2001-03-30 | 2003-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
| US6355682B1 (en) * | 2001-05-11 | 2002-03-12 | Assa Weinberg | Treatment of acute renal failure by administration of N-acetylcysteine |
| ITMI20011863A1 (it) * | 2001-09-05 | 2003-03-05 | Zambon Spa | Associazione di farmaci contro il virus dell'influenza |
| WO2005017094A2 (en) * | 2003-08-19 | 2005-02-24 | Bioadvantex Pharma Inc. | N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency |
| ES2393674T3 (es) | 2003-11-14 | 2012-12-27 | Brigham And Women's Hospital, Inc. | Métodos para modular la inmunidad |
| ITMI20032528A1 (it) * | 2003-12-19 | 2005-06-20 | Francesco Santangelo | Uso di cistina o di cisteina per la prevenzione e il |
| US20070053970A1 (en) * | 2005-05-25 | 2007-03-08 | Guilford F T | Liposomal formulation for oral administration of glutathione (reduced) and/or methylcobalamine for diseases related to glutathione deficiency and deficiency of the methionine remethylation pathway |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4148885A (en) * | 1973-09-25 | 1979-04-10 | Institut Merieux | Immunostimulant medicine |
| FR2408387A2 (fr) * | 1975-06-30 | 1979-06-08 | Oreal | Compositions a base de dispersions aqueuses de spherules lipidiques |
| US4440788A (en) * | 1980-05-13 | 1984-04-03 | Mitsubishi Chemical Industries, Limited | Cysteine derivatives |
| US4335210A (en) * | 1981-02-11 | 1982-06-15 | Cornell Research Foundation | Method of producing L-cysteine |
| US4665082A (en) * | 1981-02-11 | 1987-05-12 | Cornell Research Foundation | Cysteine delivery system |
| US4434158A (en) * | 1981-02-11 | 1984-02-28 | Cornell Research Foundation | Cysteine delivery system |
| US4647571A (en) * | 1981-02-11 | 1987-03-03 | Cornell Research Foundation | Cysteine delivery composition |
| US4438124A (en) * | 1981-02-11 | 1984-03-20 | Cornell Research Foundation, Inc. | Cysteine delivery system |
| US4879370A (en) * | 1983-12-02 | 1989-11-07 | Cornell Research Foundation, Inc. | Glutathione delivery system |
| US4767785A (en) * | 1984-01-18 | 1988-08-30 | Michael Georgieff | Hypocaloric preparation and intravenous method for hypocaloric treatment of patients |
| US4744989A (en) * | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| EP0158487B1 (en) * | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stable composition of interleukin-2 |
| US4789633A (en) * | 1984-04-19 | 1988-12-06 | University Of Tennessee Research Corporation | Fused liposome and acid induced method for liposome fusion |
| US4710489A (en) * | 1985-04-22 | 1987-12-01 | Cornell Research Foundation, Inc. | Glutathione delivery system |
| US4758551A (en) * | 1986-07-08 | 1988-07-19 | Cornell Research Foundation, Inc. | Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types |
| DE3707127C2 (de) * | 1987-03-05 | 1996-06-20 | Zambon Spa | Verwendung von Methionin zur Behandlung von Immun-Schwächeerkrankungen bei Virusinfektionen und/oder bei Tumorerkrankungen |
| DE3812008A1 (de) * | 1987-04-10 | 1988-10-20 | Pfrimmer Pharma | Verwendung von l-(-)-thiazolidin-4-carbonsaeure als cysteinquelle bei gestoerter cysteinsynthese |
| US4895716A (en) * | 1987-06-09 | 1990-01-23 | Biogen, Inc. | Stabilized formulations of gamma interferons |
| DE3906671A1 (de) * | 1989-03-02 | 1990-09-06 | Wulf Prof Dr Droege | Orales, magenvertraegliches n-acetylcysteinpraeparat hoher dosierung |
-
1989
- 1989-09-21 CA CA000612240A patent/CA1339256C/en not_active Expired - Lifetime
- 1989-09-21 CA CA000612229A patent/CA1339070C/en not_active Expired - Lifetime
-
1990
- 1990-01-08 IE IE7390A patent/IE62795B1/en not_active IP Right Cessation
- 1990-01-12 ZA ZA90245A patent/ZA90245B/xx unknown
- 1990-01-22 MX MX019199A patent/MX173567B/es unknown
- 1990-01-23 CH CH201/90A patent/CH683499A5/it not_active IP Right Cessation
- 1990-01-24 WO PCT/US1990/000363 patent/WO1990008540A1/en not_active Application Discontinuation
- 1990-01-24 IL IL9316290A patent/IL93162A/en not_active IP Right Cessation
- 1990-01-24 NL NL9020094A patent/NL9020094A/nl not_active Application Discontinuation
- 1990-01-24 IT IT01914190A patent/IT1237999B/it active IP Right Grant
- 1990-01-24 JP JP2502885A patent/JPH04504570A/ja active Pending
- 1990-01-24 AU AU49694/90A patent/AU639686B2/en not_active Ceased
- 1990-01-24 CA CA002045180A patent/CA2045180A1/en not_active Abandoned
- 1990-01-24 DE DE19904090165 patent/DE4090165T/de not_active Ceased
- 1990-01-24 KR KR1019900702099A patent/KR940002820B1/ko not_active IP Right Cessation
- 1990-01-24 PT PT92949A patent/PT92949B/pt not_active IP Right Cessation
- 1990-01-24 TN TNTNSN90009A patent/TNSN90009A1/fr unknown
- 1990-01-25 FR FR9000839A patent/FR2643557B1/fr not_active Expired - Fee Related
- 1990-01-25 MA MA22001A patent/MA21739A1/fr unknown
- 1990-01-26 BE BE9000099A patent/BE1004168A3/fr not_active IP Right Cessation
- 1990-01-26 GR GR900100048A patent/GR900100048A/el unknown
-
1991
- 1991-06-10 GB GB9112420A patent/GB2243296B/en not_active Expired - Fee Related
- 1991-06-13 SE SE9101815A patent/SE9101815D0/xx not_active Application Discontinuation
- 1991-06-21 OA OA60026A patent/OA09503A/xx unknown
- 1991-07-17 LU LU87977A patent/LU87977A1/xx unknown
- 1991-07-25 DK DK139191A patent/DK139191A/da not_active Application Discontinuation
-
1994
- 1994-01-10 US US08/180,778 patent/US5607974A/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL9020094A (nl) | Behandeling van ziekte geassocieerd met hiv-infecties. | |
| CA2263675C (en) | Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders | |
| EP1484059B1 (en) | Antiviral compositions comprising phenylacetic acid derivatives | |
| AU768307B2 (en) | Compositions comprising methotrexate and pentostatin for treating rheumatoid arthritis | |
| JP2004536819A (ja) | ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２および治療薬を用いた複合治療 | |
| JPH07505894A (ja) | インターフェロンで病気を治療するための副作用の少ない方法および組成物 | |
| CN1094642A (zh) | 治疗组合物 | |
| US20090068253A1 (en) | Method for the treatment of infection with hhv-6 virus and the amelioration of symptoms related to virus using liposomal encapsulation for delivery of reduced glutathione | |
| US5716941A (en) | Use of methyl donor compounds to treat neurological dysfunction associated with immune defects | |
| JP2024096939A (ja) | 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物 | |
| US5580577A (en) | Method of treating the symptoms of human rhinovirus infection | |
| Cantell | Development of antiviral therapy with alpha interferons: promises, false hopes and accomplishments | |
| Santini et al. | Differentiation therapy of myelodysplastic syndromes: fact or fiction? | |
| US5108993A (en) | Pharmaceutical composition comprising zidovudine and inosiplex or components thereof for the treatment of aids-related syndromes | |
| JP2784401B2 (ja) | 慢性骨髄性白血病の治療方法 | |
| JP4580479B2 (ja) | 抗ｈｉｖ感染症剤 | |
| Anlar et al. | The effect of inosiplex in subacute sclerosing panencephalitis: A clinical and laboratory study | |
| US6306901B1 (en) | Agent for prophylaxis and therapy of diseases | |
| RU2003334C1 (ru) | Способ лечени больных с опухол ми | |
| JP2002255849A (ja) | 細胞免疫療法補助剤 | |
| Zipper et al. | Opposing effects of quinacrine and chloroquine on the development of TA3 transplanted tumors in mice | |
| JPH08169842A (ja) | 白血球増多促進剤 | |
| AU2002344860A1 (en) | Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BV | The patent application has lapsed |